Rallybio Corp short interest in 2025
In 2025, Rallybio Corp's disclosed short interest ran from 0.85% of shares outstanding on 15 Jan 2025 to 0.25% on 31 Dec 2025, a change of -0.60 percentage points. The year's high was 1.85% on 15 Aug 2025 and its low 0.25% on 31 Dec 2025, averaging 0.80% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.04 days on 14 Mar 2025. Full history: Rallybio Corp.
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 0.85% (15 Jan 2025)
- End of year
- 0.25% (31 Dec 2025)
- Change
- -0.60 pp
- High
- 1.85% (15 Aug 2025)
- Low
- 0.25% (31 Dec 2025)
- Average
- 0.80%
- Highest days to cover
- 8.04 (14 Mar 2025)
- SEC filings marked
- 8
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 0.85% | 5.36 | |
| 31 Jan 2025 | 0.84% | 7.85 | |
| 14 Feb 2025 | 0.80% | 3.87 | |
| 28 Feb 2025 | 0.81% | 5.61 | |
| 14 Mar 2025 | 0.81% | 8.04 | 10-K filed, results (8-K) |
| 31 Mar 2025 | 0.83% | 7.46 | |
| 15 Apr 2025 | 0.85% | 1.19 | |
| 30 Apr 2025 | 0.87% | 4.08 | |
| 15 May 2025 | 0.86% | 4.94 | 10-Q filed, results (8-K) |
| 30 May 2025 | 0.77% | 3.46 | |
| 13 Jun 2025 | 0.79% | 1.00 | |
| 30 Jun 2025 | 0.83% | 1.88 | |
| 15 Aug 2025 | 1.85% | 1.40 | 10-Q filed, results (8-K) |
| 29 Aug 2025 | 1.47% | 1.99 | |
| 15 Sep 2025 | 1.01% | 1.15 | |
| 30 Sep 2025 | 0.79% | 1.04 | |
| 15 Oct 2025 | 0.68% | 1.00 | |
| 31 Oct 2025 | 0.54% | 1.00 | |
| 14 Nov 2025 | 0.41% | 1.00 | 10-Q filed, results (8-K) |
| 28 Nov 2025 | 0.33% | 1.00 | |
| 15 Dec 2025 | 0.29% | 1.00 | |
| 31 Dec 2025 | 0.25% | 1.00 |
See also: Rallybio Corp's full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.